VIT32 Inhibitors
VIT32 inhibitors represent a class of compounds characterized by their molecular action of selectively interacting with a specific biological pathway. The designation 'VIT32' typically relates to the particular target or mechanism that these compounds modulate, although without further context, the specifics of this target cannot be detailed accurately. Generally, inhibitors in the context of chemistry and biochemistry are molecules that bind to enzymes or other proteins and reduce their activity. They achieve this through various mechanisms, such as competitive inhibition, where the inhibitor resembles the substrate and competes for the active site; non-competitive inhibition, where the inhibitor binds to a site other than the active site; uncompetitive inhibition, where the inhibitor only binds to the enzyme-substrate complex; and mixed inhibition, which involves elements of both competitive and non-competitive inhibition.
The chemical composition of VIT32 inhibitors is diverse, as the class may include a range of structures from small, simple molecules to complex organic compounds. What unifies them is their ability to interact with the VIT32 target in a way that modulates its function. This modulation is typically quantifiable in biochemical assays that measure the activity of the target in the presence and absence of the inhibitor. These assays help in understanding the potency, efficacy, and specificity of the inhibitor towards its intended target. The molecular interaction often involves the formation of non-covalent bonds between the inhibitor and the target, such as hydrogen bonds, ionic bonds, hydrophobic interactions, and van der Waals forces. These interactions are carefully studied through techniques like X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and molecular docking simulations to elucidate the exact binding mode of the inhibitors and to understand the structural basis of their inhibitory action. This detailed structural knowledge is critical to the development and refinement of these compounds, ensuring a high level of specificity and potency for the intended molecular target.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent non-specific inhibitor of protein kinases. It acts by binding to the ATP binding site of these kinases, which could lead to the inhibition of kinase-mediated phosphorylation required for the activation or function of VIT32. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3K, a kinase involved in the PI3K/Akt signaling pathway. Inhibition of PI3K leads to a decrease in Akt phosphorylation, which could indirectly result in reduced activation or downstream signaling of VIT32 if VIT32 is a downstream effector in this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTOR, which is part of the mTOR signaling pathway. This pathway is involved in cell growth, proliferation, and survival. Inhibition of mTOR would lead to decreased protein synthesis and cell proliferation, potentially reducing the levels of VIT32 if it is a protein whose expression is regulated by mTOR activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. This kinase is involved in the response to stress stimuli and inflammatory cytokines. Inhibition of p38 MAPK can decrease the activation of transcription factors that may regulate the expression of VIT32, thus indirectly decreasing its functional activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway. By inhibiting MEK, the subsequent phosphorylation and activation of ERK are prevented. If VIT32 is regulated by ERK-mediated signaling or requires ERK activity for its function, this would result in the functional inhibition of VIT32. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Lapatinib is an inhibitor of the tyrosine kinases EGFR and HER2. By blocking the activity of these receptors, downstream signaling pathways that may involve VIT32 could be affected, resulting in decreased functional activity of VIT32 if it is a part of these pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets Raf kinases, VEGFR, and PDGFR. Its inhibition of these kinases can alter cell signaling pathways that regulate cell proliferation and survival, potentially affecting VIT32 activity if VIT32 is involved in these pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, preventing the activation of the MAPK/ERK pathway. If VIT32 function or stability is dependent on signaling through this pathway, inhibition by U0126 would lead to decreased functional activity of VIT32. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor that can prevent the degradation of proteins involved in cell cycle regulation. If the stability or turnover of VIT32 is regulated by the ubiquitin-proteasome system, the use of bortezomib could lead to altered VIT32 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Sp600125 is an inhibitor of JNK, which is part of the MAPK signaling pathways. Inhibition of JNK can affect transcription factors and other signaling molecules that may be involved in the regulation of VIT32 expression or activity. | ||||||